Hormonal
Multi-agonists (GLP-1/Glucagon, GLP-1/GIP, or GLP-1/GIP/Glucagon) show greater potential for weight loss than single-agonists by combining appetite suppression with increased energy expenditure.
Newer 'multi-agonist' drugs that target multiple hormones (like GLP-1, GIP, and Glucagon) are in development. They aim to lose weight by both reducing hunger and increasing energy burn. These are not yet widely available for obesity treatment but show promise for those who need more than standard therapies.
A single drug that acts at two or more different receptors may enhance weight loss compared with single receptor agonists... Glucagon receptor stimulation enhances energy expenditure... GLP-1 receptor stimulation on satiety
Why this rating
Based on early clinical trials and preclinical data; results are promising but not yet fully established for routine clinical use.
Source
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al. · Diabetes Therapy · 2020
DOI 10.1007/s13300-020-00816-y
More from this paper
- GLP-1 receptor agonists (specifically high-dose liraglutide 3.0 mg) produce clinically significant weight loss (5.9 kg/year) by enhancing satiety via hypothalamic stimulation and delaying gastric emptying.Good
- SGLT-2 inhibitors produce modest weight loss (2.1-2.7 kg) in people with Type 2 Diabetes by inducing glucose-mediated osmotic diuresis, but are not yet approved specifically for obesity treatment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →